Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.68 |
| ▸ | EGFR | P00533 | 9/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569993 | 0.93 | ERBB2 (0.71) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5566204 | 0.91 | ERBB2 (0.63) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5566215 | 0.91 | ERBB2 (0.63) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5566538 | 0.91 | ERBB2 (0.65) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5635817 | 0.89 | ERBB2 (0.76) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5636008 | 0.86 | ERBB2 (0.85) | ERBB2EGFRKCNH2 | |
| SCHEMBL5570127 | 0.85 | ERBB2 (0.73) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5568831 | 0.84 | ERBB2 (0.86) | ERBB2EGFRKCNH2 | |
| SCHEMBL5569075 | 0.83 | ERBB2 (0.86) | ERBB2EGFRKCNH2 | |
| SCHEMBL5636356 | 0.82 | ERBB2 (0.84) | ERBB2EGFRKCNH2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 4/4885KCNH2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.